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Abstract  
Remyelination failure plays an important role in the pathophysiology of MS, but the 
underlying cellular and molecular mechanisms remain poorly understood. We now report 
actively demyelinating lesions in patients with MS are associated with increased glial 
expression of fibroblast growth factor 9 (FGF9) which we demonstrate inhibits 
myelination and remyelination in vitro. This inhibitory activity is associated with the 
appearance of multi-branched “pre-myelinating” MBP+/PLP+ oligodendrocytes that 
interact with axons but fail to assemble myelin sheaths; an oligodendrocyte phenotype 
described previously in chronically demyelinated MS lesions. This inhibitory activity is not 
due to a direct effect of FGF9 on cells of the oligodendrocyte lineage but is mediated by 
factors secreted by astrocytes. Transcriptional profiling and functional validation studies 
demonstrate that these include effects dependent on increased expression of tissue 
inhibitor of metalloproteinase (TIMP)-sensitive proteases, enzymes more commonly 
associated with extracellular matrix remodeling. Further, we found that FGF9 induces 
expression of Ccl2 and Ccl7, two pro-inflammatory chemokines that contribute to 
recruitment of microglia and macrophages into MS lesions. These data indicate glial 
expression of FGF9 can initiate a complex astrocyte-dependent response that contributes 
to two distinct pathogenic pathways involved in the development of MS lesions. Namely, 
induction of a pro-inflammatory environment and failure of remyelination; a combination 
of effects predicted to exacerbate axonal injury and loss in patients.  
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Introduction  
Experimental studies demonstrate the default response to immune mediated 
demyelination in the central nervous system (CNS) is rapid remyelination by 
oligodendrocytes derived from an endogenous pool of mitotic NG2+ oligodendrocyte 
progenitor cells (OPC; Tripathi et al., 2010). However, in multiple sclerosis (MS) this 
repair mechanism frequently fails resulting in chronically demyelinated plaques of gliotic 
scar tissue (Franklin & ffrench-Constant, 2008). This has profound pathophysiological 
consequences as loss of myelin not only disrupts axonal function per se, but also 
compromises the physical integrity of affected axons by increasing their susceptibility to 
inflammatory mediators (Redford et al., 1997) and disrupting trophic support provided by 
myelinating oligodendrocytes (Fünfschilling et al., 2012). This combination of effects will 
exacerbate axonal loss in patients (Nave, 2010; Franklin et al., 2012) and restoring 
endogenous remyelination is now considered an attractive strategy to prevent further 
axonal damage and restore function (Irvine and Blakemore, 2008; Duncan et al., 2009; 
Deshmukh et al., 2013). However achieving this goal in MS requires a far better 
understanding of why remyelination fails and how this is related to the inflammatory 
component of the disease.  
 
Failure of remyelination is not due to an intrinsic defect in cells of the oligodendrocyte 
lineage as demonstrated by the presence of remyelinated “shadow plaques” in many 
patients at autopsy (Patani et al., 2007; Patrikios et al., 2006; Prineas et al., 1993; 
Raine and Wu, 1993;  Prineas and Connell, 1979). However the efficacy of this 
endogenous repair mechanism declines with disease progression (Goldschmidt et al., 
2009; Patani et al., 2007). Studies in rodents suggest this may be due to the cumulative 
effects of repeated or sustained episodes of inflammatory demyelination on OPC 
recruitment or survival (Linington et al., 1992), which will be exacerbated by effects 
related to normal ageing (Shen et al., 2008). Nonetheless in patients the mechanisms 
responsible for failure of remyelination remain obscure. The continued presence of 
significant numbers of OPC in many lesions suggests this involves factors that inhibit 
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OPC differentiation (Kuhlmann et al., 2008; Wolswijk, 2002; Chang et al., 2002; 
Scolding et al., 1999), although effects reducing OPC recruitment and/or survival will 
also impact on remyelination efficacy (Piaton et al., 2009). 
  
Experimental studies suggest a large number of different mechanisms are available that 
might inhibit OPC differentiation and remyelination in MS. These include factors affecting 
interactions with extracellular matrix components, altered availability of growth factors 
and/or OPC guidance cues or which trigger inappropriate re-expression of developmental 
signaling pathways (reviewed in Kotter et al., 2011). Convincing arguments are available 
to support a role for each of these in lesion development, but their relative importance 
with respect to failure of remyelination remains unclear. Resolving this question is 
important as it will determine which effector pathway(s) provide the most appropriate 
target for treatment strategies designed to restore endogenous remyelination.  
 
One potential target is signal transduction by members of the fibroblast growth factor 
(FGF) family (Bansal, 2002; Mohan et al. 2014) which play important roles in 
coordinating neuronal and glial differentiation and survival during CNS development 
(Guillemot and Zimmer, 2011). In the context of MS, previous studies focused on the 
possible involvement of FGF2 (Sarchielli et al., 2008), a pleiotrophic growth factor 
expressed by macrophages and microglia in active white matter lesions (Clemente et al., 
2011). However, it is difficult to deduce the functional significance of increased 
expression as FGF2, since it can exert both potentially beneficial as well as detrimental 
effects in the adult CNS. On one hand it may limit axonal loss by virtue of its 
neuroprotective properties (Ruffini et al., 2001; Rottländer et al., 2011) or enhance 
remyelination by supporting the expansion and specification of OPC derived from neural 
stem cells (McKinnon et al., 1990; Azim et al., 2012). However any benefit provided by 
these effects are thought to be negated by other effects that may inhibit OPC 
differentiation and compromise remyelination (Bansal, 2002; Butt and Dinsdale, 2005; 
Tobin et al., 2011; Azim et al., 2012; Mierzwa et al., 2013). Unravelling the 
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pathophysiological significance of FGF2 is complicated further by expression of other FGF 
family members in the CNS that signal using the same FGF receptor (FGFR) isoforms 
(Tacer et al., 2010; Mohan et al., 2014). These include FGF9 that is expressed 
constitutively by many adult neurons, and mimics the ability of FGF2 to suppress myelin 
protein expression by differentiating OPC (Cohen and Chandross, 2000); an observation 
that led us to investigate whether it might also contribute to lesion formation in MS.  
 
We now report lesion formation is associated with increased expression of fibroblast 
growth factor 9 (FGF9) by astrocytes and oligodendrocytes and demonstrate this 
pleiotropic growth factor inhibits myelination and remyelination in vitro. This is not due 
to a direct effect of FGF9 on cells of the oligodendrocyte lineage, but is an off target 
effect mediated by soluble astrocyte-derived factors that inhibit the terminal 
differentiation of myelinating oligodendrocytes. In tissue culture this is associated with 
the appearance of multi-branched “pre-myelinating” oligodendrocytes that extend 
processes which interact with axons, but fail to form myelin sheaths; an oligodendrocyte 
phenotype reminiscent of that seen in chronically demyelinated MS lesions (Chang et al., 
2002).  
 
Transcriptional profiling of myelinating cultures revealed FGF9 modulated expression of 
genes involved in several pathways identified previously as contributing to failure of 
remyelination in MS, in particular several associated with components of the extracellular 
matrix (ECM) (Kotter et al., 2011). These included effects predicted to impact on 
remyelination due to altered CD44/hyaluronan signaling (Tuohy et al., 2004; Back et al., 
2005; Chang et al., 2012; Bugiani et al., 2013), as well as increased expression of 
chondroitin sulfate proteoglycans (Siebert et al., 2011) and fibronectin (Maier et al., 
2005; Sisková et al., 2006, 2009; Stoffels et al., 2013)]. These changes were associated 
with significantly increased expression of mRNAs encoding ADAMTS1 and other 
metalloproteases associated with ECM remodeling. Subsequent experiments confirmed 
increased expression/activity of these tissue inhibitors of metalloproteinases (TIMP)-
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sensitive proteases contribute significantly to the mechanisms by which FGF9 inhibits 
myelination. In addition FGF9 also induced an innate immune signature characterized by 
increased astrocytic expression of Ccl2 and Ccl7; pro-inflammatory chemokines that 
contribute to the development of inflammatory responses in the CNS (Fuentes et al., 
1995; Mahad and Ransohoff, 2003; Trujillo et al., 2013; Renner et al., 2011; Thompson 
and Van Eldik, 2009).  
 
In summary our data demonstrate FGF9 can initiate a complex astrocytic response 
predicted to compromise remyelination, while at the same time stimulating 
microglial/macrophage recruitment in MS lesions; a combination of effects predicted to 
exacerbate axonal loss and accumulation of disability in patients with progressive MS 
(Franklin et al., 2012). We suggest inhibition of FGF-mediated signal transduction in 
astrocytes may provide an effective target for treatment strategies that simultaneously 
enhance endogenous remyelination and suppress intrinsic pro-inflammatory responses in 
the CNS.  
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Methods  
Immunohistochemical analysis of human tissues 
Immunohistochemical studies were performed on archived formalin-fixed, paraffin-
embedded brain material from 14 patients with MS and six controls without neurological 
disease or evidence of brain lesions (Table 1). Immunohistochemical studies were 
performed on consecutive deparaffinized 5 µm sections after endogenous peroxidase was 
blocked with H2O2/methanol. Antigen retrieval was performed using citrate buffer (pH 
6.0) and non-specific antibody binding was blocked by incubating sections in 10% fetal 
calf serum. Primary antibodies to FGF9 (rabbit polyclonal, Abcam, 1:1,000), carbonic 
anhydrase II (CAII; sheep polyclonal, The Binding Site, 1:1,000), glial fibrillary acidic 
protein (GFAP; mouse monoclonal; Neomarkers; 1:200) and amyloid precursor protein 
(APP; mouse monoclonal; Chemicon, 1:1,000) were applied overnight at 4°C. Antibody 
binding was routinely visualized using appropriate species-specific horse radish 
peroxidase conjugated secondary antibodies and 3,3’-diaminobenzidine (DAB). Cell 
nuclei were counterstained with hematoxylin prior to mounting.  
Fluorescence double immunostainings were successfully performed on biopsy tissue from 
5 patients with early active demyelinating lesions using anti-FGF9 (Abcam, 1:400), anti-
NogoA (11C7, 1:4000, kindly provided by Martin Schwab, University and ETH Zurich, 
Switzerland) and anti-GFAP (Dako, mouse monoclonal; 1:300) antibodies respectively. 
Anti-rabbit-Cy3 (1:200) and anti-mouse-Alexa488 (1:500) secondary antibodies were 
used to detect bound primary antibodies. Sections were counterstained with DAPI. The 
density of FGF9 immunoreactive astrocytes was determined using an ocular 
morphometric grid at a magnification of 400x. Demyelinating lesion areas as well as 
periplaque tissue (3/5) and normal appearing white or grey matter (3/5) were available 
for analysis. Astrocytes were identified by virtue of their nuclear and cytoplasmic 
morphology. The percentage of FGF9-immunoreactive astrocytes was determined for 
lesion and periplaque tissue. 
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Cell culture 
Dissociated myelinating cultures were generated as described previously (Elliott et al., 
2012). Briefly, neurospheres were generated from striata of P1 Sprague-Dawley rats by 
resuspending dissociated cells in 20ml neurosphere media [DMEM/F12 (1:1, DMEM 
containing 4,500 mg/L glucose), supplemented with 0.105 % NaHCO3, 2 mM glutamine, 
5,000 IU/ml penicillin, 5µg/ml streptomycin, 5.0 mM HEPES, 0.0001% bovine serum 
albumin, (all from Invitrogen), 25 µg/ml insulin, 100 µg/ml apotransferrin, 60 µM 
putrescine, 20 nM progesterone, and 30 nM sodium selenite (all from Sigma)] and plating 
them in a 75 cm3 tissue culture flask. The culture was supplemented with 20 ng/ml mouse 
submaxillary gland epidermal growth factor (R&D Systems), and maintained at 37ºC in a 
humidified atmosphere of 7% CO2/93% air. Every 2-3 days, 5 ml NSM and 4 µl EGF were 
added to the flask. Neurosphere-derived astrocytes (NsAs) were obtained by triturating 
neurospheres and plating them onto Poly-L lysine (PLL, 13 µg/ml) coated cover slips (13 
mm diameter, VWR International, Leicestershire, UK) in low glucose DMEM supplemented 
with 10% fetal bovine serum (FBS) and 2 mM L-glutamine (Sigma) until they formed a 
confluent monolayer.  
 
NsAs conditioned media was obtained from confluent NsAs monolayers grown in DM 
without insulin (see below) in the presence or absence of 100 ng/ml FGF9 for three days. 
These supernatants were immediately used to treat myelinating cultures (3:1 vol/vol 
supernatant/fresh DM without insulin) from 18 to 28 days in vitro (DIV) in the presence or 
absence of a neutralizing antibody specific for human FGF9 (R&D Systems, 10 µg/ml).  
 
Myelinating spinal cord cultures were derived from E15.5 Sprague-Dawley (SD) 
embryos. Spinal cords were dissected out, meninges removed, minced with a scalpel 
blade and enzymatically dissociated with 2.5% trypsin (Invitrogen) and 1.33% 
collagenase (ICN Pharmaceuticals, UK). Enzymatic activity was stopped by adding 1 ml 
of a solution containing 0.52 mg/ml soybean trypsin inhibitor, 3.0 mg/ml bovine serum 
albumin, and 0.04 mg/ml DNase (Sigma). The tissue was then triturated, centrifuged 
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and resuspended in plating medium (PM, 50% DMEM, 25% horse serum, 25% HBSS), 
and thereafter 150,000 cells in 50 µl were plated on cover slips coated with a confluent 
monolayer of NsAs. Coverslips were placed in 35-mm Petri dishes (3 per dish) and left in 
the incubator to attach for 2 hours, and subsequently 450 µl of PM and 600 µl of 
differentiation medium (DM) [DMEM (4,500 mg/ml glucose), 10 ng/ml biotin, 0.5% 
hormone mixture (1 mg/ml apotransferrin, 20 mM Putrescine, 4 µM progesterone, and 6 
µM selenium; formulation based on Bottenstein and Sato, 1979), 50 nM hydrocortisone, 
and 0.1 µg/ml insulin (all reagents from Sigma) was added. Every two days 500 µl of 
media was withdrawn and replaced by fresh DM media. From 12 DIV onwards cultures 
were fed with insulin free DM. The effect of recombinant human FGF9 and other soluble 
factors (all obtained from R&D Systems) on myelinating cultures was investigated 
between 18 and 28 DIV. To block proliferation, cultures were treated with 20 µM cytosine 
β-D-arabinofuranoside (AraC, Sigma). ADAMTS and MMP activity was inhibited by adding 
a cocktail containing 3µg/ml recombinant human tissue inhibitor of metalloproteinases 1, 
-2 and -3 (TIMP-1, -2 and -3; all from R&D Systems). 
 
A2B5+ OPCs were isolated from P1 rat cortex. Briefly, meninges were removed and 
tissue digested with a neural tissue dissociation kit containing Papain (Miltenyi Biotec) 
according to the manufacturer’s instructions. Tissue was digested for 25 min at 37°C and 
then dissociated manually to give a single cell suspension. Cells were centrifuged at 
300xg for 10 min, after which OPCs were purified by MACS magnetic bead separation 
using anti-A2B5 MicroBeads (Miltenyi Biotec). A2B5+ cells were resuspended in Basal 
Chemically Defined medium (BDM: DMEM, 4 mM L-glutamine, 1 mM sodium pyruvate, 
0.1% BSA, 50 ug/ml apo-transferrin, 5 ug/ml insulin, 30 nM sodium selenite, 10 nM D-
biotin and 10 nM hydrocortisone) containing 20 ng/ml PDGF-AA and 20 ng/ml FGF2 and 
plated on PLL (13 µg/ml) coated coverslips at a density of 1 -2 x 104 cells / cm2. After 3 
DIV PDGF/FGF2 was withdrawn and cells were allowed to differentiate for up to 7 days in 
modified Sato’s medium (Bottenstein and Sato, 1979; DMEM containing 4,500 mg/L 
glucose, 2 mM glutamine, 5,000 U/ml penicillin, 5 µg/ml streptomycin, 10 µg/ml insulin, 
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100 µg/ml apo-transferin, 16.1 µg/ml putrescine, 60 ng/ml progesterone, 30 nM sodium 
selenite, 0.4 µg/ml triiodo-L-thyronine, 0.4 µg/ml L-thyroxine T4, and 0.1 mg/ml BSA) in 
the absence or presence of FGF9. Cells were fed twice a week by replacing half the 
culture supernatant with fresh media.  
 
Organotypic slice cultures 
Organotypic cultures were established and analysed as described previously (Zhang et al, 
2011). Briefly, P1-P2 mouse pups were decapitated and their brains were placed into ice-
cold Hank’s Balanced Salt Solution (HBSS). Cerebellum and brainstem were cut into 200-
300µm sagittal slices using a McIlwain tissue chopper. The slices were placed onto 
Millicell-CM organotypic culture inserts (Millipore) in medium containing 50% MEM with 
Earle’s salts, 25% Earle’s Balanced Salt Solution, 25% heat-inactivated horse serum, 
glutamax-II supplemented with penicillin-streptomycin, amphotericin B (Invitrogen) and 
6.5 mg/ml glucose (Sigma). Medium was changed every two days. After 10 days in 
culture, demyelination was induced by addition of 0.5mg/ml lysophosphatidyl lysolecithin 
(LPC; Sigma) to the medium for approximately 16 hours, after which the slices were 
transferred back into normal medium +/- 100ng/ml FGF9. Cultures were maintained for a 
further 14 days and then fixed with 4% paraformaldehyde (PFA) in phosphate-buffered 
saline (PBS) for 1 hour whilst still attached to the membrane inserts. They were then 
rinsed in PBS for 10 mins (x3) and blocked with 3% heat inactivated horse serum, 2% 
bovine serum albumin (BSA), and 0.5% Triton X-100 in PBS for 1 hour. Slices were 
incubated with primary antibodies overnight, washed with PBS once for 10 min and then 
three times for 1 hour. Appropriate secondary antibodies (AlexaFluor, Invitrogen) were 
then applied overnight after which the slices were washed twice for 1 hour in PBS and 
then mounted.  
 
Primary antibodies used for these studies were specific for: myelin oligodendrocyte 
glycoprotein (MOG, 1:500, Abcam), myelin basic protein (MBP, 1:500, Serotec), 
proteolipid protein (PLP, 1:100, AA3 hybridoma supernatant supplied by S. Barnett), and 
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neurofilament (NFH, 1:50000, EnCor). Myelination was quantified by confocal microscopy 
as described previously (Zhang et al, 2011) using stacks of images of myelin (MOG/MBP) 
and neurofilament immune labelling obtained at 1µm intervals in white matter areas at 
x40 magnification. Four slices (4 image stacks) were quantified per treatment/control and 
the experiment repeated three times using cultures from different litters of P1 mice.  
 
Immunofluorescence microscopy 
Cultures were fixed with 4% PFA for 20 min at RT, washed in PBS, permeabilised in 
0.5% Triton X-100 / PBS for 15 min at RT, washed with PBS, and blocked with 1% BSA / 
10% Horse serum / PBS for 1 hour at RT. Primary antibodies used were: SMI-31 
(1:1500, Abcam), Z2 (anti-MOG, 1:200, clone Z2), PLP/DM20 (1:100, hybridoma 
supernatant supplied by S. Barnett), MBP (1:100, Millipore), O4 (1:500, R&D Systems), 
NG2 (1:200, Millipore), Olig2 (1:1000, Millipore), Caspr (1:500, Abcam) and GFAP 
(1:500, Dako). These were diluted in blocking buffer and incubations performed either at 
room temperature (RT) for 1 hour or overnight at 4°C. After gentle washing bound 
antibodies were visualized using appropriate combinations of species/isotype specific 
fluorochrome-conjugated secondary antibodies (1:400, Invitrogen) after incubation at RT 
for 15 minutes. Cover slips were then washed with PBS followed by distilled water and 
mounted with Mowiol4-88 (Calbiochem, UK) containing the nuclear stain DAPI. Cell 
proliferation was analyzed using the Click-iT EdU Alexa Fluor 594 Kit (Invitrogen) 
following manufacturer’s instructions, co-stained with DAPI and other markers and 
imaged. Images were captured using an Olympus BX51 fluorescent microscope and 
Image-Pro software. For quantitative analysis of neurite density and myelination, 10 
random images from each of three coverslips were taken at 10× magnification. All 
experiments were performed in triplicate providing a total of 270 images per condition 
for quantification and analysis. Neurite density was quantified as described previously 
(Elliott et al., 2012), myelination and cell counts were quantified using CellProfiler cell 
image analysis software (Carpenter et al., 2006). The pipe lines developed for this study 
are available at https://github.com/muecs/cp. 
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In situ hybridization analysis  
In situ hybridization studies were carried out using fresh frozen tissue samples provided 
by the UK Multiple Sclerosis Tissue Bank (UK Multicentre Research Ethics Committee, 
MREC/02/2/39). Synthetic digoxigenin-labeled riboprobes (cRNA) were generated from 
recombinant pCRTMII-Topo® plasmid containing a 606 bp cDNA insert of human FGF9 
sequence (5’-2809-3414-3’). Transcription was done from both sides with either SP6 or T7 
RNA polymerase, generating antisense or sense (control) cRNA probes. In situ 
hybridization was performed on cryosections of freshly frozen tissues as described 
previously (Schaeren-Wiemers and Gerfin-Moser, 1993; Graumann et al., 2003). In situ 
hybridization signal was revealed by alkaline phosphatase with BCIP and NBP as 
substrate. For immunohistochemistry tissue sections were washed twice with PBS, 
thereafter sections were treated with 0.6% hydrogen peroxide in methanol for 30 min and 
with blocking buffer (1% normal donkey serum, 0.1% Triton, 0.05% Tween) for 1 h. 
Sections were incubated with the following primary antibodies overnight at 4°C: rabbit 
anti-Olig2 (1:500, Millipore), and rabbit anti-GFAP (1:2000, DakoCytomation). Secondary 
biotinylated antibodies (Vector Laboratories, 1:500) were applied for 2 h at room 
temperature, followed by ABC complex reagent (Vector Labs) for 30 min. Colour reaction 
was performed with 3-amino-9-ethylcarbazole. Luxol fast Blue (LFB) and 
hematoxylin/eosin (HE) stainings were performed according to standard protocols. 
 
RNA extraction and microarray analysis  
RNA was extracted from myelinating cultures grown in the presence or absence of FGF9 
(100 ng/ml) for 24h using the Qiagen RNeasy Micro kit according to manufacturer’s 
instructions. RNA quality and integrity was checked using the Agilent Bioanalyzer 6000 
Nano LabChip platform. RNA was then used for microarray expression analysis and 
quantitative reverse transcription (qRT)-PCR. The total RNAs were processed and 
labelled with biotin using Ambion® WT Expression Kit following the Affymetrix 
GeneChip® WT Terminal Labeling and Hybridization protocol. The processed RNAs were 
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hybridized to Affymetrix GeneChip® Rat Gene 1.0 ST Arrays using manufacturer's 
protocols for using the Fluidics Station 450. The hybridized arrays were scanned on the 
Gene Array Scanner 3000-7G. The data analysis was carried out in Partek Genomics 
Suite (version 6.6, Partek Inc., St. Louis, MO, USA) software. Control (CTR) and 
Treatment (FGF) groups were generated with three replicates per group. This dataset 
has been deposited in the Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/ accession number GSE52753). Probe set level data 
were normalized using the GCRMA normalization method and summarized to transcript 
cluster level using One-Step Tukey's Biweight method. Differential expression analysis 
was carried out by performing a Two-way ANOVA test on the normalized expression 
values. Differentially expressed gene lists were generated based on the ANOVA log2 fold 
change > ± 1.4 (± 2.639 fold change in linear scale) at a FDR adjusted p-value of 
<0.01. The differentially expressed genes were analyzed in Partek Pathway for enriched 
pathways utilizing the Kegg database for rat.  
 
Quantitative real-time PCR 
Changes in expression of selected genes of interest was verified using RNA obtained 
from additional myelinating cultures and monolayers of NsAs grown in the presence or 
absence of FGF9. Following RNA extraction, cDNA was synthesized using the Qiagen 
QuantiTect® Reverse Transcription Kit following the manufacturer’s instructions. Cycling 
parameters were as follows: first cycle (DNA wipeout step) 42°C for 2 min, after adding 
reverse transcriptase, reaction buffer and primer mix second cycle: 42°C for 20 min, 
then 3 min for 95°C. Real-time PCR was performed using 1X SYBR Green master mix 
(Applied Biosystems), 10 ng cDNA template, 50 pmol/µl of each primer and distilled 
water. Primers were designed using the NCBI nucleotide data base and Primer 3 
software (http://biotools.umassmed.edu/bioapps/primer3_www.cgi) (Rozen and 
Skaletsky, 2000). Primer sequences were checked with BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and were purchased from Sigma or IDT. The 
reaction was amplified in an Applied Biosystems Fast Real-Time PCR System (ABI 7500) 
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using the following cycle settings: 50°C for 5 min, 95°C for 10 min, followed by 40 
cycles of 95°C for 15 s, 60°C for 1 min, and a final dissociation step at 95°C for 15 s. 
Melt curve analysis was then performed between 75–99°C in 1°C increments. The 
comparative CT method (or the 2-∆CT method) (Livak & Schmittgen, 2001; Schmittgen 
& Livak, 2008) was used to determine differences in gene expression between FGF9 and 
control samples. For statistical analysis, a paired two-sample t-test was used on the 
mean ∆CT for each experimental repeat. 
 
ELISA 
CCL2 and Hyaluronan concentrations were measured in supernatants harvested from 
myelinating cultures (DIV18) or astrocytes monolayers grown in the presence or absence 
of FGF9 for 24 hrs using mouse/rat CCL2 or Hyaluronan Quantikine ELISA kits (R&D 
Systems) according to the manufacturer’s instructions. Aggrecanase activity was 
assayed in supernatants from myelinating cultures (DIV18) treated with or without FGF9 
for 72 hrs using an ELISA-based Aggrecanase Activity Assay Kit (Abnova) following 
manufacturer’s instructions. In brief, enzyme activity was assessed by the capacity of 
test samples to digest a recombinant fragment of human aggrecan. This proteolytic 
cleavage releases an ARGSVIL-peptide that is then quantified by ELISA using appropriate 
specific antibodies.  
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RESULTS 
Tissue damage in multiple sclerosis is associated with increased expression of 
FGF9 
We investigated FGF9 expression in post mortem CNS tissue from 7 control donors and 
in white matter lesions from fourteen cases of MS (6 acute, 1 relapsing remitting, 7 
chronic; Table 1). In agreement with previous studies (Todo et al., 1998) FGF9 was 
expressed constitutively by neurons and occasionally by glia and cells associated with 
the vasculature (Fig. 1A). Neurons exhibited a punctate pattern of cytoplasmic staining 
that was superimposed on a background of extracellular immunoreactivity which may be 
due to FGF9 in axons and/or dendrites, or bound to components of the extracellular 
matrix. FGF9 immunoreactivity was far less pronounced in subcortical white matter in 
which weak staining was observed in scattered neurons, and less frequently in 
astrocytes and oligodendrocytes (Fig. 1B). This contrasted to the situation in MS which 
was associated with a generalized increase of FGF9 immunoreactivity in white matter, in 
particular in active lesions, defined by the abundance of macrophages, containing early 
myelin degradation products (Fig. 1C-D). Staining was most pronounced in 
oligodendrocytes, although astrocytes and other cells, putatively identified as OPC were 
also immunoreactive (Fig. 1F). This was not only seen in acute active lesions, but was 
also observed, albeit to a lesser extent, at the rim of slowly expanding white matter 
lesions from patients with longstanding progressive disease (Fig. 1 G-I). Normal 
appearing white matter exhibited variable immunoreactivity in oligodendrocyte-like cells, 
astrocytes and vessel associated cells that were intermediate between that in control 
white matter and active lesion areas (Fig. 1E). However, FGF9 immunoreactivity was 
minimal in the center of slow expanding white matter lesions apart from occasional 
weakly staining astrocytes (Fig. 1J). A similar lack of staining for FGF9 was apparent in 
chronic inactive lesions (Fig. K, L) where immunoreactivity for FGF9 was restricted to 
occasional axonal spheroids, and cells morphologically consistent with being astrocytes 
and endothelial cells (Fig. 1M, N). 
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The cellular distribution of FGF9 immunoreactivity in active lesions was then examined in 
more detail using biopsies of early active demyelinating lesions. This confirmed neurons, 
GFAP+ astrocytes and occasional NogoA+ oligodendrocytes can all express FGF9 in these 
lesions, but also revealed there was substantial variation in the number of FGF9 
immunoreactive glia between cases (Supplementary Figure 1).  Although on average 
approximately half of the astrocytes in these lesions (50.94 + 0.08 percent) and 
surrounding periplaque grey matter (50.67 + 0.12 percent) were immunoreactive for 
FGF9. In contrast no FGF9+ reactive astrocytes were detected in normal appearing grey 
matter in the three cases where this was available. In addition to this pronounced 
astrocytic response a small number of occasional NogoA+ cells expressing FGF9 were 
also detected in and around these early demyelinating lesions (Supplementary Figure 
1).  
To determine whether glial immunoreactivity for FGF9 was due to de novo synthesis, or 
uptake from the extracellular milieu we performed in situ hybridization studies in 
combination with immunohistochemistry for Olig2 and GFAP on fresh frozen tissue 
sections from active inflammatory lesions (Fig. 2A-D, K, L) and chronic inactive lesions 
(Fig. 2E-H). This study detected variable, but high expression of FGF9 in active lesions 
(Fig. 2C and D), as well as increased expression associated with the edge of chronic 
inactive lesions (Fig. 2G and H) compared to NAWM (Fig. 2I). Immunohistochemical 
co-localization studies identified FGF9 mRNA transcripts in some but not all Olig2+ cells 
associated with these lesions (Fig. 2K, arrows), as well as in a small numbers of GFAP+ 
astrocytes (Fig. 2L, arrowheads). These findings confirm glial expression of FGF9 is up 
regulated at sites of ongoing lesion formation in MS. 
 
Increased availability of FGF9 compromises (re)myelination in vitro  
FGF9 plays important roles in co-ordinating cell proliferation, differentiation and survival 
during development, but its expression is strongly down regulated before birth in the CNS. 
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Re-expression of FGF9 in the adult CNS might therefore be expected to have a significant 
impact on lesion development in MS; a concept supported by the ability of FGF9 to 
suppress myelin protein expression by OPC (Cohen and Chandross, 2000). We therefore 
investigated the effects of adding FGF9 to myelinating cultures derived from embryonic rat 
spinal cord by immunofluorescence microscopy, a model system that allows us to quantify 
effects on all stages of the oligodendroglial cell lineage, as well as myelination and neurite 
outgrowth. FGF9 inhibits myelination in a dose dependent manner (Figure 3A, B), >90% 
inhibition being obtained when FGF9 was present at a concentration of 100ng/ml (18 – 28 
DIV) (Figure 3B; Supplementary Figure 2). Failure of myelination was associated with 
the appearance of a population of “pre-myelinating” oligodendrocytes that exhibited a 
granular pattern of PLP and MBP immune reactivity in their cytosol. These cells were 
observed to extend processes that ended in large membrane expansions or alternatively, 
aligned along and interacted with SMI31+ neurites (Figure 3A; Supplementary Figure 
2); an oligodendrocyte phenotype associated with chronically demyelinated MS lesions 
(Chang et al., 2002).  
Inhibition of myelination by FGF9 in these cultures was accompanied by a significant 
increase in the number of Olig2+, NG2+ and PLP+ cells (Figure 3C; Supplementary 
Figure 3); an effect associated with proliferation as demonstrated by incorporation of 
EdU into cells expressing oligodendrocyte lineage-specific markers (Figure 3D). 
Incorporation of EdU was increased 3-fold in Olig2+ cells, 4 to 5-fold in O4+ cells and 
almost 10-fold in PLP+ cells. This effect of FGF9 on the oligodendroglial lineage was 
reminiscent of that reported for FGF2, a well characterized OPC mitogen which inhibits 
OPC differentiation by limiting their ability to drop out of cell cycle. We therefore 
performed experiments to determine whether this represents a generalized response to 
FGF signal transduction in this culture system. However screening nine family members 
revealed this is not the case. Only FGF9 and to a lesser extent FGF2 stimulated an 
increase in Olig2+ cell numbers while at the same time inhibiting myelination 
(Supplementary Figure 3C and D).  
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We then went on to explore whether inhibition of myelination by FGF9 in this culture 
system was dependent on maintaining OPC in cell cycle using cytosine arabinoside 
(AraC) to eliminate proliferating cells (Figure 3E; Supplementary Figure 3). Control 
experiments revealed that although treatment with AraC from 18 to 28 DIV significantly 
reduced cell proliferation this had no effect on myelination per se; an observation 
indicating myelination during this period is performed by a pre-existing pool of non-
proliferating OPC. AraC also eliminated the proliferative response induced by FGF9, 
however this failed to abrogate the effect of FGF9 on myelination demonstrating this is 
independent of its ability to act as a glial mitogen (Figure 3E). In contrast to these 
marked effects on cells of the oligodendrocyte lineage and myelination FGF9 had no 
effect on neurite density as determined by SMI31 immune reactivity (100ng/ml; DIV 18-
28; Control 77.87 +/- 3.11; FGF9 treated 77.75 +/- 5.086; percent SMI31+ pixels per 
field). 
These experiments demonstrate FGF9 inhibits myelination in a developmental setting, but 
it remained unclear whether it would also compromise remyelination. To explore this 
further we addressed this question by monitoring the effect of FGF9 on remyelination in 
cerebellar slice cultures demyelinated by treatment with LPC (Figure 4). Analysis of 
cultures 14 days after exposure to LPC revealed remyelination was significantly reduced in 
the presence of FGF9 compared to demyelinated cultures that were not exposed to this 
factor (p < 0.01) (Figure 4).  
 
FGF9 is a stage dependent mitogen for OPC  
The observation FGF9 induced OPC proliferation in myelinating cultures was unexpected 
as previous studies reported FGF9 is not a mitogen for purified OPC (Fortin et al., 2005). 
However, as OPC differentiate into mature oligodendrocytes they sequentially express 
different high affinity receptors for FGF9. Receptor expression changes from FGFR3 in 
OPC to FGFR2 in mature myelinating oligodendrocytes; activation of the latter by FGF9 
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triggering changes in process outgrowth without affecting expression of myelin proteins 
(Fortin et al, 2005). These results were however obtained after short term (48 hour) 
exposure of either early or highly differentiated progenitors to FGF9. This prompted us to 
investigate the effect of continuous exposure to FGF9 on OPC differentiation. Using 
A2B5+ progenitor cells immunopurified from the neonatal CNS we confirmed FGF9 is not 
a mitogen for OPC during their initial stages of differentiation in Sato’s medium (DIV 1 to 
3; Figure 5A). However, they subsequently become responsive to its mitogenic 
potential as later exposure (DIV 4 to 7) doubles incorporation of EdU (Figure 5A). This 
proliferative response was associated with inhibition of differentiation as demonstrated 
by analysis of cultures continuously exposed to FGF9 for 7 days; the percent of OPC 
expressing O4, PLP and MOG being reduced by 30%, 86% and >90%, respectively 
(Figure 5B, C).  
These results suggest a direct effect of FGF9 on cells of the oligodendrocyte lineage 
would account for its ability to inhibit myelination. However, our data question the 
validity of this supposition. Specifically, inhibition of myelination by FGF9 in the far more 
complex cellular environment of our myelinating cultures was neither dependent on its 
mitogenic potential (Figure 3E), nor was it associated with a net decrease in O4+ or 
PLP+ cell numbers (Figure 3C). In fact the converse was true, FGF9 increased the 
absolute number of O4+ and PLP+ cells in these cultures by 37% and 68%, respectively 
(Figure 3C). We reasoned this dichotomy could be explained by an off target effect of 
FGF9 that compensated for any direct effect of FGF9 on OPC differentiation, but which at 
the same time might also adversely affect myelination. The most likely candidates being 
astrocytes as they constitutively express FGFR3 (Young et al., 2010), a preferred high 
affinity receptor for FGF9 (Goetz and Mohammadi, 2013). 
To test this hypothesis we grew myelinating cultures (18 – 28 DIV) in the presence of 
supernatants harvested from naïve or FGF9 treated neurosphere-derived astrocytes in 
the presence or absence of a neutralizing antibody to eliminate any direct effect of 
residual FGF9. Control experiments established this antibody had no deleterious effect on 
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myelination per se, but completely neutralized the ability of FGF9 to inhibit myelination 
(Figure 5D). However, the inhibitory activity of supernatants harvested from FGF9-
treated astrocytes could not be abrogated by this FGF9-specific antibody demonstrating 
inhibition of myelination is dominated by mechanisms involving one or more astrocyte-
derived factors (Figure 5D).   
 
FGF9 activates immune and neurobiological pathways relevant for lesion 
formation  
In order to identify mechanisms by which FGF9 inhibits myelination we performed a 
microarray analysis on myelinating cultures (DIV 18) grown in the presence or absence 
of FGF9 for 24 hours. This identified 3262 transcripts differentially regulated by FGF9 
(1752 up regulated, 1510 down regulated; fold change > +/- 1.4; p<0.01; Figure 6; 
Table 2). Pathway enrichment analysis using the 731 most differentially regulated 
transcripts (fold change > +2.2; p < 0.01) identified seventeen enriched pathways (p < 
0.05; Fisher’s Exact Test; Figure 6; Supplementary Table 1). The most highly 
enriched was the cell cycle pathway, an observation that reflects the proliferative 
response to FGF9. However three of the four next most enriched pathways are 
associated with both neurobiological and immune functions (TGF-beta signaling, p = 
0.00025; cytokine-cytokine receptor interaction, p = 0.00098; Jak-STAT signaling, p = 
0.0048); an observation suggesting that in addition to any effect on remyelination 
increased availability of FGF9 may also modulate immune function within the CNS. This 
hypothesis is supported by the observation FGF9 increased expression of a cluster of 
“pro-inflammatory” genes (Ccl7, Cd93, Cd63, Ccl2, Il1rap, Tnfrsf10b and Il1r1) more 
commonly discussed in the context of innate immunity rather than their neurobiological 
effects. The relative magnitude of this effect is apparent when significance (log10 p) is 
plotted against fold change in expression which highlights the profound effects of FGF9 
on expression of Ccl7 (ranking 1; 31-fold increase), Cd93 (ranking 4; 17-fold increase), 
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Il1rap (ranking 55; 5-fold increase) and Ccl2 (ranking 56; 5-fold increase) (Figure 6; 
Table 2). This raises the possibility that in addition to its ability to inhibit 
(re)myelination, FGF9 may also promote a pro-inflammatory environment in the CNS, a 
combination of effects predicted to exacerbate axonal injury and loss in MS lesions 
(Franklin et al., 2012).  
In addition to this “pro-inflammatory” effect FGF9 modulated expression of multiple 
genes associated with pathways implicated previously in failure of remyelination. These 
include changes indicative of altered hyaluronan/CD44 signaling (Has2, Cd44; Tuohy et 
al., 2004; Back et al., 2005; Sloane et al., 2010; Bugiani et al., 2013), 
integrin/fibronectin associated effects (Itga5, Fn1; Stoffels et al., 2013), as well as 
changes predicted to affect availability of soluble factors known to support OPC 
migration, differentiation and/or survival (Stark and Cross, 2006) such as Cntf (Stankoff 
et al., 2002), Cxcl12 (Patel et al., 2010) and Fgf2 (Clemente et al., 2011).  
To identify which of these pathways might contribute to inhibition of myelination we first 
validated selected candidates by qPCR using reverse-transcribed mRNA isolated from 
myelinating cultures and astrocyte monolayers cultured for 24 hours in the presence or 
absence of FGF9. This strategy revealed FGF9 upregulated astrocytic expression of a 
number of proteases in particular ADAMTS1, ADAMTS7 and MMP3 (Table 2; 
Supplementary Table 2). These mediate a wide range of biological processes including 
extracellular matrix remodeling which led us to speculate they may adversely affect 
(re)myelination. This hypothesis received further support when assays using aggrecan as 
a “global” substrate for ADAMTS and MMP family members revealed FGF9 significantly 
increased aggrecanase activity in supernatants harvested from myelinating cultures 
(Figure 6C). To determine whether this protease activity was actively involved in 
mediating inhibition of myelination we utilized a cocktail of physiological protease 
inhibitors (TIMP1, TIMP2 and TIMP3) known to inhibit a wide range of ADAMTS and MMP 
family members. The inhibitors had no effect on myelination per se but abrogated the 
inhibitory effect of FGF9 which was reduced by approximately 37% (n = 3; FGF9 vs 
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untreated control, 78.2 +/- 5.8% inhibition, p < 0.01; FGF9 + TIMP vs untreated 
control, 49.1 +/- 11.8 inhibition, ns) (Figure 6D). Induction of TIMP-sensitive proteases 
therefore makes a significant contribution to the mechanisms by which FGF9 inhibits 
myelination in this culture system.  
Why this cocktail of inhibitors fails to completely abrogate the effect of FGF9 remains 
unclear. This may be due to incomplete inhibition of the relevant proteases, or 
alternatively involvement of other factors such as chemokines (Ccl2, Ccl7), IL-6/gp130 
cytokine family members (Il11, Lif, Cntf) and growth factors (Hbegf, Vgf, Hgf). To 
explore this possibility we screened a number of soluble factors our data suggests are 
expressed by astrocytes. For example our validation strategy indicates CCL2 is derived 
primarily from astrocytes, whereas Has2 is up regulated in some other cell type 
(Supplementary Table 2). To validate this interpretation we determined the 
concentrations of CCL2 and hyaluronic acid (HA, a surrogate marker for increased HAS2 
activity) in supernatants harvested from myelinating cultures and astrocyte monolayers 
grown in the presence or absence of FGF9 (Supplementary Figure 4). Basal 
concentrations of CCL2 were similar in myelinating cultures and astrocyte monolayers 
and up regulated to similar extents, 16- and 14-fold respectively confirming astrocytes 
were a major source of FGF9-induced CCL2 production. In contrast basal and induced 
levels of HA were far higher in supernatants harvested from myelinating cultures than 
astrocyte monolayers indicating astrocytes are not the major cellular source of HA in 
myelinating cultures. Screening selected candidates such as CCL2, CCL7 and IL-11 has 
however as yet failed to identify any that replicate the effects of FGF9. Similarly CNTF 
which is down regulated by FGF9 was unable to abrogate the effects of FGF9 
(Supplementary Figure 4).  
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Discussion 
Signal transduction by members of the FGF family influences OPC proliferation, survival 
and differentiation in the rodent CNS, observations that stimulated speculation aberrant 
FGF expression may play a role in the pathogenesis of MS (McKinnon et al., 1990; Bansal 
and Pfeiffer, 1994; Goddard et al., 2001; Oh et al., 2003; Fortin et al., 2005; Tobin et al., 
2011; Furusho et al., 2011, 2012; Mohan et al., 2014). This concept has until now 
focused on FGF2, a well characterized OPC mitogen (McKinnon et al., 1990) that is over 
expressed in MS tissues (Sarchielli et al., 2008; Clemente et al., 2011) and which acts as 
a negative regulator of remyelination in the adult CNS (Tobin et al., 2011). We now report 
expression of FGF9 is also up regulated in MS lesions and provide evidence this will result 
in a complex cellular response predicted to exacerbate disease activity in patients.  
 
Our data demonstrate expression of FGF9 is not only up regulated in early active lesions, 
but remains elevated at sites of ongoing tissue damage in patients with longstanding 
progressive disease. At these sites induction of FGF9 was observed in GFAP+ astrocytes, 
Olig2+ and occasionally more mature NOGO-A+ oligodendrocytes, a complex cellular 
response consistently associated with a background of diffuse extracellular 
immunoreactivity. The latter is attributed to FGF9 binding to heparin sulphate 
proteoglycans (HSPG) in the extracellular matrix, a property that sequesters its direct 
biological effects to the immediate vicinity of its site of synthesis (Harada et al., 2009; 
Goetz and Mohammadi, 2013). FGF9 expression was far lower in adjacent NAWM and 
largely absent in chronically demyelinated inactive lesions, a pattern that suggests 
induction represents a localised glial response to ongoing tissue damage. More detailed 
analysis of lesion biopsies revealed considerable variation in the number of FGF9 
immunoreactive glia associated with early active lesions.  
 
Whether this variation in glial expression of FGF9 is due to differences in age or 
anatomical localization of lesions is currently under investigation, as are the molecular 
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mechanisms responsible for its induction. Preliminary studies suggest this is not simply a 
glial response to T cell mediated inflammation, as increased expression of FGF9 is not 
observed in animals with experimental autoimmune encephalomyelitis (EAE). Moreover, 
FGF9 expression is increased at the active rim of slowly expanding white matter lesions 
in patients with long standing progressive disease, a site associated with minimal 
recruitment of lymphocytes from the periphery (Lassmann et al., 2012). One factor that 
might contribute to this response is decreased expression of Smad-interacting protein-1 
(Sip1) which suppresses neuronal expression of FGF9 during cortical development 
(Seuntjens et al., 2009). Intriguingly, this transcription factor is expressed by 
oligodendrocytes and plays an essential role in CNS myelination (Weng et al., 2012), an 
observation that raises the possibility Sip1 may also influence oligodendroglial 
expression of FGF9.   
Analysis of the effects of FGF9 in vitro revealed it not only inhibited 
myelination/remyelination, but also induced expression of the pro-inflammatory 
chemokines Ccl2 and Ccl7. These pleiotropic effects are mediated by high affinity 
receptors for FGF9 (FGFR2, FGFR3; Hecht et al., 1995) that are expressed by many cells 
in the CNS including astrocytes (Reuss et al., 2000; Young et al., 2010), as well as OPC 
and myelinating oligodendrocytes (Fortin et al., 2005). However, although FGF9 was 
found to inhibit the differentiation of isolated OPC into mature oligodendrocytes, this 
direct effect does not appear to be responsible for its ability to inhibit of myelination in 
the far more complex, multicellular environment of our myelinating cultures.  
We were initially perplexed by this observation as previous studies failed to report any 
significant effect of FGF9 on OPC proliferation or differentiation (Fortin et al., 2005). 
However, this earlier study only examined short term responses of early OPC or mature 
oligodendrocytes, whilst in the current study we examined the effect of continuous 
exposure to FGF9 on differentiating A2B5+ progenitors over a period of seven days. This 
revealed that as they differentiate these cells enter a stage in which they become FGF9 
sensitive; as demonstrated by their proliferative response that may reflect a 
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developmental switch in expression of FGFR3 to FGFR2 (Fortin et al., 2005). Re-entry of 
these isolated progenitors into cell cycle was associated with inhibition of differentiation 
and a corresponding decrease in the appearance of PLP+ OPC. However the reverse was 
observed when we explored the effects of FGF9 on the oligodendrocyte lineage in 
myelinating cultures. In this complex cellular environment FGF9 still acts as an OPC 
mitogen as demonstrated by EdU labeling studies, but in this case this results in a net 
increase in PLP+ cells. This dichotomy can be explained by off target effects of FGF9 on 
other cells in the culture that override or compensate for its direct effect on the 
differentiation of early progenitors. Possible candidates are astrocyte-derived “pro-
myelinating” factors such as IL-11 and LIF (Zhang et al, 2006; Ishibashi et al., 2006) 
that we found are upregulated by FGF9 in myelinating cultures. However despite any 
potential benefit this may provide, myelination was nonetheless inhibited by an 
astrocyte-dependent mechanism that inhibits differentiation MBP/PLP+ precursors into 
mature myelination-competent oligodendrocytes.  
Transcriptional profiling revealed inhibition of myelination was associated with changes in 
gene expression affecting several pathways previously implicated as causes of 
remyelination failure in MS, in particular those involving interactions with components of 
the extracellular matrix (ECM) (e.g. Adamts1, Has2, Chst3, Adamst9, Fn1, Cd44, Mmp3, 
Mmp 11, Mmp 15). These include CD44/hyaluronan signaling (Tuohy et al., 2004; Back 
et al., 2005; Chang et al., 2012; Bugiani et al., 2013), as well as effects associated with 
increased availability of chondroitin sulfate proteoglycans (Siebert et al., 2011) and 
fibronectin (Stoffels et al., 2013). The latter is of interest as fibronectin inhibits 
myelination via an integrin–dependent mechanism that disrupts vesicular traffic to sites 
of myelin assembly (Maier et al., 2005; Siskova et al., 2006, 2009); an effect that may 
contribute to the appearance of granular staining for MBP and PLP in the cytosol of 
oligodendrocytes in FGF9 treated myelinating cultures. It was also noted processes 
extended by these cells appear to be able to interact with neurites but nonetheless fail to 
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myelinate; a phenotype reminiscent of that seen in chronically demyelinated MS lesions 
(Chang et al., 2002).  
These effects were accompanied by increased expression of protease families implicated 
in ECM remodelling (Howell and Gottschall, 2012; Lau et al., 2013), in particular a 
disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS) family 
members 1, 4, 7, 9 and 14 ; matrix metalloproteinase (MMP) family members 3, 11 and 
15 and disintegrin and metalloproteinase domain (ADAM) 12. The activity of these 
metalloproteinases is regulated to differing extents by tissue inhibitors of 
metalloproteinases (TIMPs), a family of four physiological protease inhibitors. This was 
exploited to demonstrate increased expression/activity of TIMP-sensitive proteases 
contributes to the inhibitory effect of FGF9 on myelination. Further studies are now 
required to determine the relative contribution of specific proteases and their 
pathophysiological substrates. Our inability to completely abrogate the inhibitory effect 
of FGF9 on myelination using a combination of TIMP’s may indicate additional pathways 
contribute to its downstream effects on myelination. However, it should be noted the 
inhibitor cocktail used in this study only inhibited aggrecanase activity in cell culture 
supernatants by approximately fifty percent raising the possibility more complete 
inhibition could fully abrogate the effect of FGF9. Moreover, screening other potential 
candidates has as yet failed to identify any that replicate the inhibitory activity of FGF9 
(Supplementary figure 4). 
In addition to transcriptional changes indicative of ECM remodeling our micro array study 
revealed FGF9 enhanced expression of a cluster of “pro-inflammatory” genes, in 
particular Ccl7 and Ccl2; the latter being validated at the protein level. These 
chemokines are expressed in MS lesions where they are thought to be involved in 
recruiting macrophages and microglia (McManus et al., 1998). This ability of FGF9 to 
induce this “pro-inflammatory” response and at the same time inhibit remyelination has 
major implications with respect to its role in disease pathogenesis. Traditionally MS is 
viewed as an inflammatory disease driven by autoimmune response in the periphery, but 
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immunomodulatory treatments that target this response and disease activity in RRMS 
generally fail to benefit patients with progressive forms of the disease. These immune 
modulatory treatments are thought to fail because accumulation of disability in these 
patients is driven by inflammatory mechanisms sequestered within the CNS that are 
largely independent of T cell recruitment from the periphery (Lassmann et al., 2012). 
Our data suggest glial expression of FGF9 will contribute to this scenario by virtue of its 
effects on astrocytes that inhibit remyelination and generate a pro-inflammatory 
chemokine response; a combination of effects predicted to exacerbate axonal loss while 
simultaneously recruiting more inflammatory cells into the developing lesion (Franklin et 
al., 2012). In summary our data identify FGF signaling in astrocytes as a novel target for 
both regenerative and anti-inflammatory therapies in MS.  
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Figure 1. FGF9 is up regulated in multiple sclerosis lesions. 
(A) In control grey matter we detected intense extensive granular FGF9 
immunoreactivity in the cytoplasm of cortical neurons superimposed on weaker diffuse 
granular immunoreactivity in the parenchyma. We also observed weak granular 
reactivity in some glia cells (arrows) and in association with the vessel wall (arrowhead). 
(B) Immunoreactivity was less pronounced in subcortical white matter although we still 
detected immunoreactivity in neurons (arrows), as well as weak reactivity in occasional 
cells with astrocyte morphology (arrowheads). (C and D) Active MS lesion of a patient 
with acute MS. (C) Myelin is lost in the plaque (right) in comparison to the periplaque 
white matter and is taken up by macrophages in the lesions. Immunocytochemical 
staining for myelin oligodendrocyte glycoprotein. (D) Immunocytochemistry for 
macrophages shows profound infiltration of the lesion (right) and massive microglia 
activation at the lesion edge (left). (E) Expression in normal appearing white matter is 
intermediate between that seen in active lesions and control white matter and is 
characterized by variable staining of oligodendrocyte-like cells (arrow), astrocytes 
(arrowhead) and vessel associated cells (asterisk). (F) Immunoreactivity for FGF9 was 
far more pronounced in active lesions compared to control white matter. Strong 
expression was observed in cells with oligodendrocyte morphology (arrows), weaker 
expression in astrocytes (arrowheads) as well as other cell types, possibly OPC. Rim of 
an early active lesion from case of acute MS, disease duration, 2 months. (G, H) Slowly 
expanding lesions in progressive MS are defined by myelin loss and the presence of 
some macrophages at the lesion border with myelin degradation products (G); there is 
massive microglia activation at the lesions edge and some immunoreactive cells have 
macrophage morphology (H). (I) FGF9 immunoreactivity is increased at the edge of 
slowly expanding white matter lesions from cases of progressive disease. In this case 
immunoreactivity is associated with axonal spheroids (arrows) and glia (arrowhead). Rim 
of a slowly expanding lesion from a case of primary progressive MS. (J) The center of 
chronic active lesions show very limited astrocytic immunoreactivity for FGF9. (K, L) 
Page 41 of 58
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
41 
 
Inactive lesions show myelin loss with a sharp border towards the periplaque white 
matter (PPWM) (K) and no immunoreactivity for macrophage antigens (e.g. CD68) 
within or around the lesion (L). Immunoreactivity for FGF9 across inactive chronic 
lesions is far lower than in control white matter as seen at the lesion rim (M) where 
immunoreactivity is associated with an axonal spheroid (arrow) as well as weaker and 
variable staining of glia (arrowheads). In the center of the same lesion (N) weak 
immunoreactivity is seen associated with a single cell, morphologically consistent with an 
endothelial cell. (K-N) Inactive lesion from a case of secondary progressive MS with a 
duration of > 35 years. Bar in all panels corresponds to 20 µm. 
 
Figure 2. In active lesions FGF9 is expressed by cells of the oligodendrocyte 
lineage.  
In situ hybridization was performed on fresh frozen postmortem MS brain tissues with 
active and chronic active white matter lesions identified by Luxol Fast Blue (LFB) (A and 
E, respectively). B and F show the corresponding HE staining of consecutive tissue 
sections. In situ hybridization for FGF9 transcripts show high level of expression within 
active lesion (C and D, higher magnification), increased expression in the edge of 
chronic active lesions (G and H, higher magnification), and high expression in cerebral 
cortex (I), whereas in NAWM FGF9 is expressed at low levels (H and I). 
Immunohistochemical colocalization detects FGF9 transcripts mainly in Olig2-positive 
cells (K, arrows), but also in a small number of GFAP-positive cells (L, arrows) although 
most GFAP-positive cells were negative (arrowhead). Bar corresponds to 500 µm in A-C, 
E-G and I; to 100 µm in D and H, and to 25 µm for K and L. 
 
Figure 3.  FGF9 inhibits myelination and expands OPC numbers in vitro. 
Oligodendrocytes in untreated cultures myelinate multiple axons (A); MBP (red) 
reactivity is predominantly associated with myelin sheaths, whilst PLP (green) 
immunoreactivity is also present in the oligodendrocyte cell body. Treatment with 100 
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ng/ml FGF9 from 18-28 DIV is associated with the appearance of multi-branched 
oligodendrocytes that exhibit a granular staining pattern for MBP and PLP in the cell body 
and fail to generate myelin sheaths. MBP, red; PLP, green; SMI3,1 blue. Bar corresponds 
to 20 µm. Inhibition of myelination by FGF9 in these cultures is dose dependent (B); 
myelination was quantified using a MOG-specific antibody as described in the text. This 
is associated with treatment increased numbers of Olig2+ (p<0.001), NG2+ (p<0.01) and 
AA3+ (p<0.01) cells. There was also a trend for O4+ cell numbers to increase, but this 
did not reach significance (p=0.055) (C). This increase in OPC numbers was due to  
proliferation as demonstrated by the presence of increased numbers of Olig2, O4 and 
AA3 (PLP/DM20) immunoreactive cells labelled with EdU (DIV 18 – 22) (D). However the 
ability of FGF9 to inhibit myelination is independent of this proliferative response as 
inhibition of proliferation by cytosine arabinoside (AraC, 20 µM) was unable to abrogate 
inhibition of myelination by FGF9 (E).    Data are presented as means ± SEM obtained 
from a minimum of 3 experiments; * p<0.05; ** p<0.01; *** p<0.001. 
 
Figure 4. FGF9 compromises remyelination in organotypic slices. 
Cerebellar slices from postnatal day 2 mouse pups were cultured for 10 days and then 
demyelinated using LPC for 16 hours. Cultures were then allowed to remyelinate over 
the next 14 days in the presence or absence of FGF9 (100 ng/ml) after which 
remyelination was assessed using antibodies specific for MOG and PLP to label myelin, 
and NFH to label axons. Confocal immunofluorescence microscopy shows treatment with 
FGF9 leads to less remyelination (A) as demonstrated by the reduction in MOG+ 
internodes (red) and PLP+ internodes (green) encasing NFH+ axons (blue). Scale bar 10 
µm. Remyelination was quantified using image analysis to define co-localization of 
staining for myelin (PLP+ or MOG+) and axons (NFH+) (B) - a quantification of 
myelinated internodes we term the remyelination index (amount of myelin/axon).  
Irrespective of the antibody used to identify myelinated internodes, treatment with FGF9 
(F) reduced remyelination compared to untreated cultures (C). Mean +/- SEM (n = 3, at 
least 6 slices per experiment; *** p<0.001; ** p<0.01  
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Figure 5. FGF9 inhibits OPC differentiation directly and induces secretion of 
myelination-inhibiting factors by astrocytes. 
Proliferation of immunopurified A2B5+ OPC cultured in the presence or absence of FGF9.  
FGF9 is not initially an OPC mitogen (DIV 1–3), but progenitors become responsive as 
they differentiate (DIV 4-7) (A). This proliferative response is associated with inhibition 
of OPC differentiation assessed using three stage specific markers (O4, PLP and MOG) 
(B, C). Panel B provides representative images demonstrating the effect on expression 
of PLP and MOG. Bar represents 100 µm. Supernatants from FGF9 treated and untreated 
neurosphere-derived astrocytes were harvested and added to myelinating cultures in the 
presence or absence of a neutralizing anti-FGF9 antibody (10 µg/ml) from 18 to 28 DIV 
(D). Quantifying PLP+ myelination reveals the FGF9-specific antibody neutralized the 
ability of FGF9 to inhibit myelination, but failed to block inhibitory activity present in 
supernatants harvested from FGF9-treated astrocytes. A, C, D: data represent means ± 
SEM from at least three independent experiments; p<0.001 ***; p<0.01 **; p<0.05 *, 
n.s. = not significant. 
 
Figure 6. Transcriptional profiling of the effects of FGF9 in myelinating cultures. 
(A) Pathway enrichment analysis based on KEGG databases of the 731 most 
differentially regulated transcripts after FGF9 treatment identified seventeen significantly 
enriched pathways. Shown are the five most highly enriched pathways with enrichment 
p-values and up- or down-regulated genes. 
(B) Volcano plot of fold-change versus log10 significance reveals FGF9 up regulated a 
cluster of pro-inflammatory genes (dark blue) including Ccl7 and Ccl2; induced 
expression changes indicative of extracellular matrix remodeling (red); modulated the 
relative expression of IL6/gp130 gene family members (light blue) and uniformly 
reduced expression of myelin associated genes.  
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 (C) Aggrecanase activity was assayed in supernatants from myelinating cultures grown 
in the presence or absence of FGF9 for 72 hours. Cell culture supernatants protolytically 
cleave a recombinant aggrecan substrate into ARGSVIL-peptide which is then measured 
by ELISA. Data represents the mean ± SEM of 7 independent experiments, p<0.05 *. 
(D) Myelinating cultures were treated with FGF9 for 10 days in the absence or presence 
of tissue inhibitors of metalloproteinases (TIMP-1, -2 and -3; each at 1 µg/ml) after 
which myelination was quantified as described in the text. This cocktail of TIMPS had no 
effect on basal levels of myelination, but abrogated inhibition of myelination by FGF9. 
Representative data (mean ± SEM) from one of three independent experiments.  
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Tab. 1 
Summary of FGF9 expression in healthy controls and multiple sclerosis patients  
    FGF9 expression 
Patient ID Disease type Age Gender GM WM NAWM Lesion rim Lesion core 
8-04-1 control 36 F +++ +    
579-91-3 control 46 M +++ +    
28-03-2 control 42 F +++ +    
132-92-4 control 65 M +++ +    
421-91-5 control 80 F ++ +    
68-93-4 control 83 M +++ +    
581-96-10D acute MS 35 M ++  + +++ ++ 
90-09-6 acute MS 69 F +++  + +++ ++ 
A01-144 acute MS 34 F +++  + +++ ++ 
S403-97 acute MS 45 M +++  + ++ ++ 
270-99-2 acute MS 45 M +++  + ++ ++ 
70-93-6 acute MS 78 M +++  + +++ +++ 
Spanien C2 RRMS 40 F +++  + ++ ++ 
39-03-15 chronic active 67 M +++  - + - 
146-01-8 chronic active 41 M +++  - + - 
144-90-3 chronic active 77 F +++  - + - 
67-05-9 chronic active 34 M +++  - + - 
244-94-7 chronic inactive 81 F +++  - - - 
285-81-1 chronic inactive 78 F +++  - - - 
72-83-6 chronic inactive 64 F +++  - - - 
GM = gray matter, WM= white matter, NAWM= normal appearing white matter, RRMS= relapsing remitting multiple sclerosis 
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Tab. 2 
Genes shown in the volcano plot 
# gene fold change p-value rank 
pro-inflammatory genes  
1 * ccl7 31.03 7.28E-20 1 
2   cd93 17.48 9.60E-17 4 
3   cd63 8.89 7.42E-17 21 
4   il1rap 4.96 1.32E-18 55 
5 * ccl2 4.96 6.46E-17 56 
6   tnfrsf10b 3.19 2.50E-11 110 
7   il1r1 2.04 1.88E-07 426 
8 * cxcl12 -1.59 4.40E-03 28267 
extracellular matrix genes 
9   *adamts1 19.83 1.60E-16 2 
10   itga5 7.04 1.64E-15 29 
11   igfbp3 6.67 4.37E-17 32 
12  adam12 5.33 2.30E-10 49 
13 * has2 5.09 2.89E-11 51 
14 *adamts7 4.74 2.50E-14 60 
15   chst3 3.59 4.96E-16 88 
16   adamts9 2.93 4.20E-10 131 
17   adamts14 2.84 5.26E-18 143 
18 * cd44 2.65 2.61E-16 179 
19   fn1 2.13 4.42E-06 371 
20  adamts4 2.08 2.47E-09 397 
21   lama5 1.71 1.63E-07 778 
22   mmp15 1.67 4.30E-12 833 
23   *mmp3 1.65 4.00E-05 860 
24   itgb1 1.58 6.28E-11 1062 
25   itgb8 1.54 1.47E-13 1184 
26   icam1 1.44 6.36E-06 1554 
27   mmp11 1.43 1.11E-03 1627 
IL6/gp130 family genes 
28 * clcf1 14.19 5.92E-20 6 
29 * il11 9.26 1.47E-15 19 
30 * lif 5.70 3.42E-11 42 
31   osmr 2.26 5.20E-13 302 
32   il6 1.26 7.39E-03 3104 
33   stat2 -2.11 5.91E-10 28775 
34 * cntf -2.42 4.04E-11 28895 
myelin genes 
35   plp1 -1.39 1.18E-11 27534 
36   cnp -1.51 3.51E-10 28057 
37   opalin -1.60 2.61E-05 28296 
38 * mog -1.69 3.45E-08 28414 
39   omg -1.70 1.14E-12 28443 
40 * mbp -1.72 6.02E-09 28479 
41 * mag -1.74 8.45E-09 28497 
42   mobp -2.93 4.52E-12 29021 
other genes 
43 * hbegf 10.86 7.99E-17 11 
44 * vgf 4.56 2.58E-12 65 
45 * fgf2 1.55 7.14E-09 1140 
46 * hgf -8.02 1.39E-20 19788 
highest rank corresponds to highest fold change 
* genes validated by qPCR 
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Supplementary Tab.1: 
Enriched pathways after FGF9 treatment (KEGG database) 
pathway name enrichment p-
value 
% genes 
in the 
pathway 
name of genes enriched 
Cell cycle 1.5e-06 
 
13.7 
 
Bub1↑ Bub1d↑ Ccna2↑ Ccnb1↑ Ccnd1↑ Cdc6↑ Cdk1↑ 
Cdkn2b↑ Mcm3↑ Mcm5↑ Mcm6↑ Myc↑ Orc1↑ Tgfb2↓ 
Tgfb3↑ Ttk↑ 
TGF-β signalling 2.5e-04 
 
12.8 
 
Bmp4↓ Bmp6↓ Cdkn2b↑ Id3↓ Id4↓ Ltbp1↑ Myc↑ Smad9↑ 
Tgfb2↓ Tgfb3↑ 
Malaria 6.6e-04 15.6 Ccl2↑ Hgf↓ Met↑ Sdc1↑ Tgfb2↓ Tgfb3↑ Vcam1↓ 
Cytokine-cytokine 
receptor interaction 
9.8e-04 
 
8.0 
 
Ccl2↑ Ccl7↑ Clcf1↑ Cntf↓ Eda2r↑ Hgf↓ Il1rap↑ Il11↑ Lif↑ 
Met↑ Osmr↑ Pdgfrb↓ Tgfb2↓ Tgfb3↑ Tnfrsf12a↑ Tnfrsf19 
Jak-STAT signalling 4.8e-03 
 
8.3 
 
Ccnd1↑ Clcf1↑ Cntf↑ Il11↑ Lif↑ Myc↑ Osmr↑ Socs3↑ 
Spred3↑ Spry2↑ Spry4↑  
DNA replication 5.1e-03 14.7 Mcm3↑  Mcm5↑ Mcm6↑ Pole↑ Rpa2↑ 
Ether lipid 
metabolism 
6.5e-03 
 
13.9 
 
Enpp2↓ Enpp6↓ Pla2g5↓ Plb1↑ Ppap2b↓ 
p53 signaling 
pathway 
1.4e-02 
 
10.2 
 
Ccnb1↑ Ccnd1↑ Cdk1↑ Igfbp3↑ Rrm2↑ Serpine1↑ 
 
Lysine degradation 1.9e-02 
 
10.6 
 
Aadat↓ Aass↓ Bbox1↓ Plod1↓ Plod3↑ 
 
Glutathione 
metabolism 
1.9e-02 
 
10.6 
 
Gss↑ Gstm2↓ Mgst1↓ Oplah↓ Rrm2↑ 
 
HTLV-I infection 2.3e-02 
 
5.8 
 
Bub1b↑ Ccnd1↓ Cdkn2b↑ Egr1↑ Egr2↑ Fosl1↑ Mybl1↑ 
Mybl2↑ Myc↑ Pdgfrb↓ Pole↑ RT1-S3↓ Tgfb2↓ Tgfb3↑ 
Vcam1↓ Wnt7b↑ 
Complement and 
coagulation 
cascades 
2.6e-02 
 
8.8 
 
C1s↓ C3↓ F3↑ Plau↑ Plaur↑ Serpine1↑ 
 
Glycerolipid 
metabolism 
2.7e-02 
 
9.8 
 
Agpat2↑ Lipg↑ Mboat1↑ Mgll↓ Ppap2b↓ 
 
Fat digestion and 
absorption 
3.7e-02 
 
10.5 
 
Abca1↓ Agpat2↑ Pla2g5↓ Ppap2b↓ 
 
Vitamin digestion 
and absorption 
4.0e-02 
 
13.0 
 
Folh1↓ Plb1↑ Tcn2↓ 
Arachidonic acid 
metabolism 
4.8e-02 
 
7.6 
 
Cyp2j3↓ Cyp4f1↓ Cyp4f4↓ Pla2g5↓ Plb1↑ Tbxas1↑ 
 
Nicotinate and 
nicotinamide 
metabolism 
4.9e-02 
 
12.0 Aox1↓ Naprt1↓ Nt5c1a↓ 
upregulated ↑downregulated ↓ 
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Supplementary Tab. 2:  
Validation of selective candidates in myelinating cultures and astrocyte monolayers by qPCR 
 
 
Microarray Myelinating 
cultures 
Astrocytes Primer pair 
Gene Fold 
change 
p-value Fold 
change 
p-
value 
Fold 
change 
p-value Sequence 5’ to 3’ 
 
CCL2 
 
4.96 
 
*** 
 
97.62 
 
*** 
 
39.65 
 
** 
TAGCATCCACGTGCTGTCTC 
TGCTGCTGGTGATTCTCTTG 
 
 
CCL7 
 
31.03 
 
*** 
 
294.79 
 
*** 
 
61.11 
 
*** 
CCATCAGAAGTGGGTTGAGG 
CAGAAAGGACAAGGGTGAGG 
 
 
ADAMTS1 
 
 
19.83 
 
*** 
 
11.99 
 
* 
 
6.95 
 
** 
AGTGGTTCCTCAGCAGCATT 
AGGGCTCCGTCTTCTTCTTC 
 
ADAMTS7 
 
 
4.74 
 
*** 
 
3.02 
 
** 
 
4.13 
 
 
** 
CTGGAAGACGAGGAGAAGGA 
GGTAAGCAGGATGGCAGTGT 
 
MMP3 
 
 
1.65 
 
*** 
 
3.66 
 
ns 
 
20.57 
 
** 
CCCGTTTCCATCTCTCTCAA 
GACATCAGGGGATTCTGTGG 
 
FGF2 
 
1.55 
 
*** 
 
0.85 
 
ns 
 
0.63 
 
ns 
AGCGGCTCTACTGCAAGAAC 
CCCTTGATGGACACAACTCC 
 
 
LIF 
 
5.70 
 
*** 
 
6.56 
 
*** 
 
4.11 
 
ns 
TCAACTGGCTCAACTCAACG 
GGCGCACATAGCTTATCCAC 
 
 
IL11 
 
9.26 
 
*** 
 
46.80 
 
*** 
 
28.51 
 
* 
CTCCCCTCGAGTGTCTTCAG 
CCATCAGCTGGGAATTTGTC 
 
 
CLCF1 
 
14.18 
 
*** 
 
39.19 
 
 
*** 
 
16.26 
 
** 
TGCTTCCCTACCCCAATAACT 
TGTCCCTGCCCTTCTCTTT 
 
 
HBEGF 
 
10.86 
 
*** 
 
18.30 
 
*** 
 
17.10 
 
ns 
GACCGATCTGGACCTTTTCA 
TTTCCTAACCCCTTGCCTTT 
 
 
VGF 
 
4.56 
 
*** 
 
17.19 
 
*** 
 
16.71 
 
* 
TCTCTGACCATTTGCACGAC 
GGCAACGTGAAGGTTTTCAT 
 
 
HGF 
 
-8.02 
 
*** 
 
-5.58 
 
*** 
 
-12.44 
 
* 
TCCTCTCGTTCCTTGGGATT 
TCGCAGTTGTTTTGTTTTGG 
 
 
CNTF 
 
-2.42 
 
*** 
 
-3.20 
 
* 
 
-14.08 
 
** 
TGGCTAGCAAGGAAGATTCG 
TCACTCCAACGATCAGTGCT 
 
 
CD44 
 
2.65 
 
*** 
 
9.01 
 
*** 
 
3.48 
 
ns 
ATGGAGTTAGCCCTGAGCAA 
TTGTTGGCTGCACAGATAGC 
 
 
HAS2 
 
5.09 
 
*** 
 
9.08 
 
*** 
 
1.36 
 
ns 
GACCTCCATTCCGCTCTTG 
TTTTCCCCTGTTTTGCTATTT 
 
 
CXCL12 
 
-1.59 
 
*** 
 
-3.41 
 
* 
 
-5.35 
 
* 
CCAAACTGTGCCCTTCAGAT 
TGGGCTGTTGTGCTTACTTG 
 
 
MOG 
 
-1.69 
 
*** 
 
-3.03 
 
* 
 
n.d. 
 
n.d. 
GCAGGTCTCTGTAGGCCTTG 
GGCACTCTCAGGAAGTGAGG 
 
 
MAG 
 
-1.74 
 
*** 
 
-3.02 
 
* 
 
n.d. 
 
n.d. 
TCGCCTCACTGTACTTCACG 
GAGGCAGGTGGTAAGGAAT 
 
 
MBP 
 
-1.72 
 
*** 
 
-2.48 
 
* 
 
n.d. 
 
n.d. 
TACCCTGGCTAAAGCAGAGC 
AGGGAGCCGTAGTGGGTAGT 
 
p< 0.05*, p<0.01**, p<0.001***, ns= not significant, n.d.= not determined 
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